Biochemical Status of Beta-Thalassemia Major Patients in Erbil City

Case Control study


  • Omar Surchi College of Medicine, Hawler Medical university
  • Sarkawt Ali Maxillofacial Department, College of Dentistry, Hawler Medical University



β- thalassemia, Serum


Background and objectives: β -thalassemia major patient is one of the hereditary hemolytic diseases, which can cause many hematological and biochemical changes in the affected patient. And these changes can happen even when the patient is treated adequately. The objective was to study biochemical changes in the level of serum hepcidin, osteocalcin, calcium, ferritin, iron, PTH and IL-6 in patients with β- thalassemia major and to compare it with control subjects.

Patients and method: In this research 40 patients with beta thalassemia major, 20 Female and 20 Male (age ranged from 10 to 38 years), and 40 control subjects 20 Female and 20 Male (age ranged from 9 to 33 years) were studied. Measurement of serum hepcidin, osteocalcin, calcium, ferritin, iron, PTH and IL-6 were done by the researcher for both cases and control groups.

Results: Serum Ferritin and Iron were higher significantly in all thalassemic patients (P< 0.001), this increment was proportional with increasing number of units of blood transfusion and aging. Mean serum Hepcidin, PTH, Osteocalcin and IL6 were significantly lower in thalassemic patients in contrast to the control subjects (P< 0.001). Reduction in S-PTH was proportional to increasing number of blood transfusion and aging.

Conclusion: Our study demonstrates that in B-thalassemia major patients Serum Ferritin and Iron were increased proportionally with increasing age and number of units of blood transfusion. Mean serum PTH, osteocalcin, hepcidin, and IL-6 were reduced, but mean serum calcium was remained normal. 


1.Walker B, Colledge N, Ralston S, Penman I. Davidson's principles and practice of medicine.22nd edition. 2014; page 1034.
2.Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–10.
3.Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of in ammation.Blood. 2007;109(9):4038– 44.
4.Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Chris- takis J, et al. Mutant antimicrobial peptide hepcidin is as- sociated with severe juvenile hemochromatosis.Nat Genet. 2003;33(1):21–2.
5.Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoas- say for human serum hepcidin. Blood. 2008;112(10):4292–7.
6. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haemato- logica. 2006;91(6):727–32.
7. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007;48(1):57–63.

8. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalas- semia. Haematologica. 2007;92(5):583–8.
9. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood. 2013;122(1):124–33.
10. Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vich- insky EP, et al. Iron homeostasis during transfusional iron over- load in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr He- matol Oncol.2007;24(4):237–43.
11.Nemeth E. Hepcidin in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:31–5.

12.Hamdi RA. Evaluation of Serum Osteocalcin level in Iraqi Postmenopausal women with primary osteoporosis. J Fac Med Baghdad. 2013;55(2):166-69.
13.Civitelli R, Armamento- Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporosis Int. 2009;(20):853-51.
14.Jagtap VR, Ganu JV, Nagane NS. BMD and serum intact osteocalcin in post- menopausal osteoporosis women. Ind J Clin Biochem. 2013;26(1):70-73.

15. Hamidieh AA, Moradbeag B, Pasha F, Jalili M, Hadjibabaie M, Keshavarznia M. Hypoparathroidism in patients with beta thalassemia major. IJHOSCR. 2009; 3:17-20.
16. Wieliczko M, Dylewska M. Hypocalcemia. Wiad Lek. 2013; 66:303-6.
17.Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. J Trace Elem Med Biol 2012; 26(26): 115-119. 

18.Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-spe- cific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40(2): 255-263.
19.Kaplan J, Ward DM, De Domenico I. The molecular basis of iron overload disorders and iron-
linked anemias. Int J Hematol 2011; 93(1): 14-20.
20.Smith KA. Interleukin-2: inception, impact, and implications. 
Science 1988; 240:1169-76. 

21.Van Snick J. Interleukin 6: an overview. Annu Rev Immunol 
1990; 8:253-78.
22.Pakbaz Z, Fischer R, Fung E, Peter Nielsen RD, Harmatz P, Vichinsky E (2007) Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and Sickle cell patients. Pediatr Blood Cancer 49:329–332
23.Hagag AA, Elfrargy MS, Gazar RA, Abd El-Lateef AE. Therapeutic value of combined therapy with Deferasirox and Silymarin on iron overload in children with beta- thalassemia. Mediterr J Hematol Infect Dis. 2013;5:e2013065
24.Muhammad J, Iram A , Muhammad T S , Ghazala M, Saima I, Shahida M. Hepcidin Levels in Multi Transfused β Thalassemia Major Patients. Journal of Rawalpindi Medical College (JRMC); 2016;20(3):206-208
25.Chauhan R, Sharma S, Chandra J. What regulates hepcidin in poly-transfused β-Thalassemia Major: Erythroid drive or store drive?. Indian Journal of Pathology and Microbiology.2014 ;57(1):39-42.)
26. Basha N KP , Shetty B, Shenoy UV . Prevalence of hypoparathyroidism (HPT) in beta thalassemia major. J Clin Diagn Res. 2014; 8:24-6.
27. Habeb AM, Al-Hawsawi ZM, Morsy MM, Al-Harbi AM, Osilan AS, Al-Magamsi MS, et al. Endocrinopathies in beta-thalassemia major. Prevalence, risk factors, and age at diagnosis in Northwest Saudi Arabia. Saudi Med J. 2013; 34:67-73.
28.Napoli N1, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum calcium levels of 25- hydroxy vitamin D in adults with thalassemia major or intermedia. Bone. 2006; 38:888-92.
29.Saboor M, Qudsia F, Qamar K, Moinuddin M. Levels of calcium, corrected calcium, alkaline phosphatase and inorganic phosphorus in patients’ serum with β- thalassemia major on subcutaneous deferoxamine. J Hematol Thrombo Dis. 2014; 2:130.
30.Goyal M, Abrol P, Lal H (2010) Parathyroid and calcium status in patients with thalassemia. Indian J Clin Biochem 25: 385-387.
31.Abdel Hafez M, Abdel Fatah S, El Sokkary S, El Dammasy H, Mahfouz K. Thyroid functions in b-thalassemia major in Egyp- tian children. Egypt J Haematol 1999;7(1–2):46–65.
32.Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematologic disorders. Br J Haematol 1987; 67:377-80.
33. Zoga J, Refatllari E, Allkanjari A et. al. Biochemical markers of bone disease in patients with β-thalassaemia major in the center of hemoglobinopathy Lushnja, Albania. Int J Health Sci Res. 2014;4(12):139-143.
34. Oztürk O et al. Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia major. Haematologia, 2001, 31:237–244.




How to Cite

Surchi O, Ali S. Biochemical Status of Beta-Thalassemia Major Patients in Erbil City: Case Control study. EDJ [Internet]. 2018 Jun. 6 [cited 2022 Jun. 26];1(1):1-9. Available from:



Original Articles